J P Morgan Chase & Co's price objective would suggest a potential upside of 50.17% from the stock's current price.
A number of other equities analysts have also commented on the company. Finally, Cann assumed coverage on Editas Medicine in a research note on Monday, July 17th.
The company's consensus rating on Reuter's scale slipped from 1.71 to 1.62 during a month. Zacks Investment Research lowered Editas Medicine from a "buy" rating to a "hold" rating in a research note on Tuesday, July 18th. Research firm Zacks lifted Editas Medicine from a "hold" recommendation to a "buy" recommendation and fixed a $19.00 price target for The corporation in a note on Wed, Jul 12th. crowd sourced stock rating company Vetr lifted Editas Medicine from a "buy" recommendation to a "strong-buy" recommendation and fixed a $27.14 target price for The corporation in a note on Mon, Mar 20th. SunTrust Banks, Inc. began coverage on Editas Medicine in a report on Thursday, July 13th. The brokerage set a "hold" rating and a $17.00 price target on the stock. Wall Street is only getting more bullish on the stock, with 3 of analysts who cover EDIT having a buy-equivalent rating. According to Thomson Reuters, sell-side analysts are forecasting a harmony target price of $102.29 on company shares.
Editas Medicine, Inc. (NASDAQ:EDIT) has been the object of insider buying and selling activity recently.
Editas Medicine, Inc. has a 52 week low of $12.43 and a 52 week high of $29.20. The stock is trading at $19.72 which is well above the 50 day moving average which is $16.99 and marginally over the 200 day moving average of $18.99. The firm's market capitalization is $898.04 million.
Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, August 9th. Editas Medicine had a negative return on equity of 69.21% and a negative net margin of 2,091.36%. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $2.20 million. During the same quarter past year, the firm posted ($0.54) EPS. Clough Capital Partners L P now owns 392,087 shares of the company's stock valued at $8,751,000 after buying an additional 341,687 shares in the last quarter.
EPS growth in next year is estimated to reach -4.30% while EPS growth estimate for this year is set at -47.00%.
Recent Trading for Editas Medicine, Inc. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US and global trademark and copyright legislation. The correct version of this article can be accessed at https://weekherald.com/2017/08/12/creative-planning-purchases-9000-shares-of-editas-medicine-inc-nasdaqedit.html. (NASDAQ:EDIT). Gerald Frank Cox, Chief Medical Officer purchased $56,600 worth of shares at an average price of $14.15 on June 2nd. The shares were purchased at an average price of $14.07 per share, with a total value of $492,450.00.
Kevin Bitterman, Director disclosed the sale of 1,000,000 shares of (EDIT). The shares were sold on May 22nd for an average price of $17.00.
And it remains to be seen which target price EDIT can achieve without sacrificing much as the company is holding a -8.28% fall for the past twelve months. Russell Investments Group bought a fresh position in stocks of Editas Medicine throughout the Q4 valued about $284,000. Bank of America Corp DE raised its position in shares of Editas Medicine by 72.2% in the first quarter.
The stock of Editas Medicine Incorporated (NASDAQ:EDIT) registered an increase of 9.47% in short interest. Creative Planning now owns 9,101 shares of the company's stock worth $153,000 after buying an additional 9,000 shares during the last quarter. As of the end of the quarter Tiaa Cref Investment Management LLC had acquired 131,389 shares growing its stake by 715.7%. Goldman Sachs Group Inc. now owns 34,559 shares of the company's stock worth $771,000 after buying an additional 4,945 shares in the last quarter. Finally, Barrett Asset Management LLC acquired a new position in shares of Editas Medicine during the first quarter valued at $223,000. The Chief Medical Officer now owns $56,600 of the stock as reported to the SEC.
Editas Medicine, Inc is a genome editing company. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes.